Company news: Healthrageous, J&J

Share this article:
Four venture capital firms have put together $6.5 million in funding for tech firm Healthrageous, Mobihealth News reported, bringing the total amount raised to $15 million. The company offers personalized mobile and web-based tools that can help patients manage chronic conditions, and designs incentive systems based on user preferences. Mobihealth reported that the latest cash will be used to enhance user interfaces, analytics and its learning platform.

The Asbury Park Press
reports that yesterday's earnings call wasn't all about the numbers for Johnson & Johnson, and that the drug maker was once again asked if it would consider breaking the mega-corporation into independent businesses. The question was from Goldman Sachs' analyst Jami Rubin, reported the Asbury Park Press – the same analyst who wrote a 23-page note in May about just why the pharma giant should think small. CFO Dominic Caruso's response to Tuesday's query was the same response the company gave months ago: no way. “I could tell you we're not considering that now, and we feel very good about having a broad-based business in healthcare,” he said. The drug maker's third quarter showed at 7% lift in sales, compared to the same period last year, with the pharma business being major contributors to the topline results. Break-up proponent Rubin has argued that divvying up the company into independent businesses would free each unit to pursue its individual needs and priorities, instead of being limited by the needs of sister divisions.
Share this article:

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.